Clinical Management Group, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia.
1] Kenton Bridge Medical Centre, Harrow, UK [2] Harrow Clinical Commissioning Group, London, UK.
NPJ Prim Care Respir Med. 2015 Jul 30;25:15050. doi: 10.1038/npjpcrm.2015.50.
The Global Initiative for Asthma (GINA) was established in 1993 by the World Health Organization and National Heart Lung and Blood Institute to develop a global strategy for managing and preventing asthma. GINA reports, now funded independently through the sale of GINA products, have provided the foundation for many national guidelines. They are prepared by international experts from primary, secondary and tertiary care, and are annually updated following a review of evidence. In 2014, a major revision of the GINA report was published, that took into account advances in evidence not only about asthma and its treatment, but also about how to improve implementation of evidence-based recommendations in clinical practice. This paper summarises key changes relevant to primary care in the new GINA report. A noticeable difference is the report's radically different approach, now clinically-focussed, with multiple practical tools and flow charts to improve its utility for busy frontline clinicians. Key changes in recommendations include a new, diagnosis-centred definition of asthma; more detail about how to assess current symptom control and future risk; a comprehensive approach to tailoring treatment for individual patients; expanded indications for commencing inhaled corticosteroids; new recommendations for written asthma action plans; a new chapter on diagnosis and initial treatment of patients with asthma-COPD overlap syndrome; and a revised approach to diagnosing asthma in preschool children. The 2014 GINA report (further updated in 2015) moved away from a 'textbook' approach to provide clinicians with up-to-date evidence about strategies to control symptoms and minimise asthma risk, in a practical, practice-centred format.
全球哮喘倡议(GINA)于 1993 年由世界卫生组织和美国国立心肺血液研究所成立,旨在制定管理和预防哮喘的全球战略。GINA 报告现通过 GINA 产品的销售独立供资,为许多国家指南提供了基础。这些报告由来自初级、二级和三级保健的国际专家编写,每年根据证据审查进行更新。2014 年,发布了 GINA 报告的重大修订版,该修订版考虑了哮喘及其治疗方面证据的进展,以及如何改善临床实践中基于证据的建议的实施。本文总结了新 GINA 报告中与初级保健相关的主要变化。一个显著的区别是报告采用了全新的、以临床为重点的方法,提供了多个实用工具和流程图,以提高其对忙碌的一线临床医生的实用性。建议中的主要变化包括:以诊断为中心的哮喘新定义;更详细地评估当前症状控制和未来风险的方法;为个体患者量身定制治疗的综合方法;扩大吸入皮质激素起始治疗的适应证;关于书面哮喘行动计划的新建议;关于哮喘-COPD 重叠综合征患者诊断和初始治疗的新章节;以及修订的学龄前儿童哮喘诊断方法。2014 年 GINA 报告(2015 年进一步更新)摒弃了教科书式的方法,以实用、以实践为中心的格式为临床医生提供了有关控制症状和最小化哮喘风险的最新证据策略。